Vun-Sin Lim, Managing Editor of the Journal of Thoracic Oncology, shared a post on LinkedIn:
“As 2025 draws to a close, here are the top 10 most cited 2025 articles in the Journal of Thoracic Oncology.
1. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial
- Peters S, Cho BC, Luft AV, et al.
- 2025 Citations: 28
- Full Article
2. High-Dose Furmonertinib in Patients With EGFR-Mutated NSCLC and Leptomeningeal Metastases: A Prospective Real-World Study
- Chen H, Yang S, Wang L, et al.
- 2025 Citations: 23
- Full Article
3. Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03
- Dowlati A, Chiang AC, Cervantes A, et al.
- 2025 Citations: 20
- Full Article
4. Risk Factors for Locoregional Relapse After Segmentectomy: Supplementary Analysis of the JCOG0802/WJOG4607L Trial
- Nakagawa K, Watanabe SI, Wakabayashi M, et al.
- 2025 Citations: 20
- Full Article
5. Differentiating Separate Primary Lung Adenocarcinomas From Intrapulmonary Metastases With Emphasis on Pathological and Molecular Considerations: Recommendations From the International Association for the Study of Lung Cancer Pathology Committee
- Chou TY, Dacic S, Wistuba I, et al.
- 2025 Citations: 19
- Full Article
6. Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929
- Karim NA, Miao J, Reckamp, et al.
- 2025 Citations: 18
- Full Article
7. Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis
- Marinelli D, Nuccio A, Federico AD, et al.
- 2025 Citations: 18
- Full Article
8. Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report
- Ou SI, Solomon BJ, Besse B, et al.
- 2025 Citations: 15
- Full Article
9. Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A
- Besse B, Goto K, Wang Y, et al.
- 2025 Citations: 14
- Full Article
10. Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC (NORA)
- Lee JB, Choi SJ, Shim HS, et al.
- 2025 Citations: 13
- Full Article
If you’re on Instagram, check out the top 10 in IASLC stories here.”
More posts featuring Vun-Sin Lim.